GUIDE.MRD Consortium Holds Productive 2nd Annual General Assembly in Hamburg
The GUIDE.MRD consortium’s 2nd annual general assembly in Hamburg discussed progress and challenges across all work packages, with over 30 pa...
EMA Approves New First-line Treatment Option for Metastatic Pancreatic Cancer
Irinotecan hydrochloride trihydrate (Onivyde pegylated liposomal) was approved in March 2024 by the European Medicines Agency (EMA). Indications: N...
“DIGESTIVE CANCER – CURRENT AND FUTURE APPROACHES FOCUSED ON PREVENTION” Highlights the Importance of Awareness and Prevention
In summary, the event was a crucial opportunity to bring together experts and the community at large to address the challenges of digestive cancer,...
Gemcitabine Plus Paclitaxel vs Gemcitabine Alone after FOLFIRINOX in Metastatic Pancreatic Cancer
GEMPAX was an open-label (both researchers and patients know which treatment is being administered), randomised (randomly assigns participants in...
F2F Consortium Meeting in Madrid
The GUIDE.MRD (Guiding multi-modal therapies against MRD by liquid biopsies) consortium partners met for the first face-to-face annual meeting...
Predictive Values of Blood-based RNA Signature for the FOLFIRINOX/FOLFOX Response in Advanced Pancreatic Cancer
Presently, no widely recognised or established biomarkers are specifically designed to predict the effectiveness of FOLFIRINOX/FOLFOX (chemotherape...
DIPLOMA Trial: Minimally Invasive Surgery is an Effective Treatment Option for Early-Stage Pancreatic Cancer
A notable study, DIPLOMA, led by Abu Hilal, M.D., Ph.D., of the Istituto Ospedaliero Fondazione Poliambulanza in Brescia, Italy, involved a large c...
Personalized mRNA Pancreatic Cancer Vaccine Shows Promising Results in Small Trial
Messenger RNA (mRNA) vaccines – famous for preventing symptomatic infection of COVID-19—are starting to show some promise against pancreati...
